R&D channel feed – Endpoints News

R&D channel feed

AstraZeneca doubles down on Moderna, invests $140M in $1.5B-plus biotech

9 years ago

Heron shares fly up after FDA (finally) approves its drug to rein in chemo side effects

9 years ago

Frustrated Eli Lilly may have to settle for a lonely last-place finish in the blockbuster CDK 4/6 race

9 years ago

Spark adds fresh evidence that pioneering gene therapy could be a game changer for patients

9 years ago

Bristol-Myers reels back in an early-stage cancer drug prospect in $60M Asia deal

9 years ago

As gene therapy rivals advance, Biogen moves closer to spinning out hemophilia drugs, R&D

9 years ago

FDA clears a Phase III path for Biogen’s BACE drug for Alzheimer’s

9 years ago

Will AbbVie bite? Decision time after Ablynx's rheumatoid arthritis drug fails a key study

9 years ago

Now a two-time loser, AstraZeneca’s hopes for selumetinib dwindle after another PhIII flop

9 years ago

Racing past a wounded Juno, Kite aims to file lead CAR-T for OK by end of 2016

9 years ago

Acetylon can say goodbye to buyout and a $1B-plus in Celgene biobucks

9 years ago

Novartis's asthma ‘wonder drug’ basks in the bright spotlight of a UK media frenzy

9 years ago

Little MEI Pharma rockets up on $25M cash injection, deep-pocket partner for PhIII AML cancer study

9 years ago

Celgene stays focused on protein homeostasis, backs Cleave’s $37M round to fuel early studies

9 years ago

Allergan, Richter steer past another late-stage pileup with cariprazine

9 years ago

Woodford gets slammed with a brutal set of portfolio hits, as Northwest continues to fester

9 years ago

Bristol-Myers craters after blockbuster checkpoint drug Opdivo fails key lung cancer study

9 years ago

Gemphire IPO staggers into the market, reaping $30M

9 years ago

Deaths derail Juno's launch countdown, giving Kite and Novartis the lead

9 years ago

Pushed by high costs in Cambridge, fast-growing Decibel makes a pioneering leap to Fenway

9 years ago

Momenta hit with a setback as pancreatic cancer drug flops in PhII

9 years ago

Regeneron makes a blockbuster case for its PhIII drug pipeline

9 years ago

Adaptimmune gets a partial hold on pivotal T-cell study, but it seems OK to breathe now

9 years ago

Takeda rests its R&D footprint on U.S. hubs

9 years ago

First page Previous page 323 324 325326327 328 329 Next page Last page